Emerging Therapies: Nucala (US) is a three-wave syndicated detailed expanded analysis that specifically tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. This report series is based on primary research data collected at one month, six months, and one year post-commercial availability of Nucala. Along with awareness and sources of familiarity, the reports assess U.S. pulmonologists’ and allergists’ trial, adoption, and use of Nucala, including anticipated future trends. The report also provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, GlaxoSmithKline’s promotional efforts, and benchmarking against previously launched immune biologic therapies. This module also includes an overview and pipeline analysis of emerging asthma therapies from early to late phase clinical development, as well as detailed profiles, expert insights, and commercial outlook for select therapies in late phase commercial development.

Table of contents

  • Nucala Launch Tracking (US) Wave 1
    • Key Findings
      • Aided Awareness of Nucala and Its Indication Is High;the Majority of Physicians Have Seen a Nucala
        • Physician Opinion
      • Who Is the Nucala Patient?
      • Who Is the Nucala Prescriber?
      • Trends and the Asthma Market
        • Trends Regarding the Uptake of Nucala: Anticipated Number of Nucala Patients
        • Physician Opinion
    • Benchmarking Nucala Launch Success vs. Various Immune Biologic Analogues
    • Prescriber and Nonprescriber Profiles
    • Nucala Awareness and Perceptions
      • Unaided and Aided Awareness of Nucala
        • Unaided Awareness of Asthma Treatments
        • Changes Made to Asthma Treatment
        • Awareness of Nucala
        • Awareness of Approved Indications for Nucala
        • Awareness of Approved Patients for Nucala
      • Familiarity with Nucala
        • Familiarity with Nucala Among Pulmonologists and Allergists
        • Level of Familiarity
      • Sources of Familiarity with Nucala
        • Ways Physicians Become Familiar with Nucala
      • Initial Reaction to and Interest in Nucala
        • Reactions to Nucala
        • Awareness Among Pulmonologists of Information on Nucala Product Profile
        • Awareness Among Allergists of Information on Nucala Product Profile
        • Level of Interest in Nucala
      • Impressions of Nucala
        • Nucala's Level of Uniqueness
        • Unaided Advantages and Disadvantages of Nucala
        • Nucala Risk-Benefit Profile Perceptions
      • Prescriber and Nonprescriber Profiles
    • Nucala Trial and Use
      • Willingness to Prescribe Nucala
      • Number of Patients Currently Receiving Nucala
        • Asthma Patients Prescribed Nucala
        • Nucala Inquiries and Starting Therapy - Pulmonologists
        • Nucala Inquiries and Starting Therapy - Allergists
        • Nucala Patients by Asthma Severity Classifications
        • Current and Discontinued Nucala Patients
        • Nucala Treatment Effect on Other Treatment Regimens
      • Reasons for Not Yet Prescribing Nucala
      • Anticipated Nucala Use
        • Patients to Be Initiated on Nucala Within One Month
        • Anticipated Timing of First Nucala Prescription
        • Patients Most Likely to Be Initially Prescribed Nucala
        • Likely Candidates for Nucala, by Asthma Severity
      • Nucala Performance on Key Attributes
        • Pulmonologists' Overall Satisfaction with Nucala
        • Allergists' Overall Satisfaction with Nucala
        • Managed Care Approval for Nucala
        • Satisfaction with Nucala Metrics Among Pulmonologists
        • Satisfaction with Nucala Metrics Among Allergists
        • Impact of Nucala Safety Concerns Among Pulmonologists
        • Impact of Nucala Safety Concerns Among Allergists
    • Effectiveness of Face-to-Face Detailing for Nucala
      • Nucala Sales Representative Frequency and Reach
        • Nucala Representative Visits and Discussions with Pulmonologists
        • Nucala Representative Visits and Discussions with Allergists
        • Materials Used by Nucala Representatives
        • Materials and Samples Provided
      • Satisfaction with Nucala Sales Representative
        • Nucala Representative Performance Rating by Pulmonologists
        • Nucala Representative Performance Rating by Allergists
      • Nucala Message Recall
        • Nucala Representative Visits and Discussions with Pulmonologists
        • Nucala Representative Visits and Discussions with Allergists
        • Patient Type Suggestions Made by Representatives to Pulmonologists
        • Patient Type Suggestions Made by Representatives to Allergists
    • Methodology
      • Physician Demographics
        • Respondent Demographics for Pulmonologists
        • Respondent Demographics for Allergists
        • Patient Demographics for Pulmonologists
        • Patient Demographics for Allergists
    • Appendix
      • Additional Primary Market Research
        • Current Treatment and Optimal Response
        • Treatment Changes
        • Reasons for Switching Asthma Treatment
        • GINA Guidelines
        • Requirements in Nucala's Managed Care Approval Process
        • Market for Alternate Administration Routes for Nucala
        • Unaided Awareness of Products in Development—Pulmonologists
        • Unaided Awareness of Products in Development—Allergists
        • Products in Development for Asthma
        • Pulmonologists' Familiarity with Products in Development
        • Allergists' Familiarity with Products in Development
        • Comments from Physicians
        • Abbreviations and Objectives

Author(s): Kristine Mackin, PhD

Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.


Related Reports

Asthma | Emerging Therapies | Dupixent (Dupilumab) (US) Wave 3

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of...

View Details

Asthma | Landscape & Forecast | Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim&rsquo...

View Details

Asthma | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details